GlassScriptPhysician profile
Anju Nair
NPI 1912323304
$1,227.82
in general payments reported to CMS, 2019-2025
18 companies · $733 in 2025
The $733 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $68.21 · 2021: $80.39 · 2022: $38.74 · 2023: $60.06 · 2024: $32.77 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $598 · Food and Beverage: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $598.20 |
| Food and Beverage | $227.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $642.85 | 2025 | |
| Heron Therapeutics, INC. | $114.77 | 2019 | |
| Janssen Biotech, INC. | $85.28 | 2019-2025 | Akeega, Erleada, Darzalex |
| Carter Bloodcare | $68.47 | 2021 | |
| Pfizer INC. | $35.20 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $33.39 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Karyopharm Therapeutics INC. | $30.72 | 2020-2024 | Xpovio |
| Geron Corporation | $25.80 | 2025 | Rytelo |
| Seagen INC. | $25.54 | 2019 | |
| Daiichi Sankyo INC. | $25.52 | 2023 | Enhertu |
| Ipsen Biopharmaceuticals, INC | $24.05 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $22.83 | 2020 | |
| Merck Sharp & Dohme LLC | $19.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.51 | 2025 | |
| Beigene USA, INC. | $16.75 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13.95 | 2019 | |
| Verastem, INC. | $13.84 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anju Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.